• Cinclus Pharma hit its enrollment target in the Phase III HEEALING1 trial for linaprazan glurate in erosive GERD.
• Randomized 521 patients, beating the protocol target of 501; primary endpoint is superiority vs lansoprazole at four-week healing in LA grade C/D.
• Topline results are expected in Q4 2026; HEEALING2 is planned to start in the US and Europe after the readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cinclus Pharma Holding AB (Publ) published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.